Evidence map›Paper›PMID 36875316›Full record

ArticleCancer diagnosis & prognosis

Clinical Outcomes and Toxicity of CT-guided High Dose-rate Brachytherapy in Women With Locally-advanced Cervical Cancer.

Vitaliana DE Sanctis, Giuseppe Facondo, Gianluca Vullo, Dimitri Anzellini, Giuseppe Sanguineti, Alessia Nardangeli, Luca Marmiroli, Francesca Tortoreto, Piercarlo Gentile, Ivan Annessi and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Radiochemotherapy and interstitial brachytherapy for cervical cancer: clinical results and patient-reported outcome measures.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Vitaliana DE SanctisRadiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
Giuseppe FacondoRadiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
Gianluca VulloRadiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
Dimitri AnzelliniRadiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
Giuseppe SanguinetiDepartment of Radiotherapy, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Alessia NardangeliDepartment of Radiotherapy, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Luca MarmiroliU.O.C. Radiotherapy, S. Giovanni Calibita Fatebenefratelli Hospital - Amethyst Radioterapia Italia, Rome, Italy.
Francesca TortoretoU.O.C. Radiotherapy, S. Giovanni Calibita Fatebenefratelli Hospital - Amethyst Radioterapia Italia, Rome, Italy.
Piercarlo GentileDepartment of Radiation Oncology, San Pietro Fatebenefratelli (FBF), Rome, Italy.
Ivan AnnessiDepartment of Radiation Oncology, San Pietro Fatebenefratelli (FBF), Rome, Italy.
Vittorio DonatoRadiation Oncology Department, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy.
Cinzia ChiostriniRadiation Oncology Department, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy.
Vincenzo TomboliniDepartment of Radiotherapy, "Sapienza" University of Rome, Policlinico Umberto I, Rome, Italy.
Francesca DE FeliceDepartment of Radiotherapy, "Sapienza" University of Rome, Policlinico Umberto I, Rome, Italy.
Maurizio ValerianiRadiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
Mattia Falchetto OstiRadiotherapy Oncology, Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, Rome, Italy.
Sapienza University of Rome · ITAzienda Ospedaliera San Camillo-Forlanini · ITFatebenefratelli Hospital · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITOspedale San Pietro Fatebenefratelli · ITPoliclinico Umberto I · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimTo evaluate the outcome and toxicities in patients with locally advanced cervical cancer (LACC) treated with radiochemotherapy and intracavitary brachytherapy. PATIENTS AND

methodsThis study included 67 patients with LACC treated between 2010 and 2018. The most represented stage was FIGO IIB. The patients were treated with external beam radiotherapy (EBRT) to the pelvis and boost to the cervix and parametrials. Concomitant chemotherapy (CHT) with cisplatin (CDDP) 40 mg/mq was planned. Subsequently, the patients underwent CT-based endouterine brachytherapy (BT). The response was evaluated at 3 months with PET-CT and/or pelvic magnetic resonance imaging (MRI). Since then, the patients have been followed with clinical instrumental controls every 4 months for the first 2 years and every 6 months for the following 3 years. Local response was assessed with pelvic MRI and/or PET-CT scan at the end of intracavitary BT) according to RECIST 1.1 criteria.

resultsThe median duration of treatment was 55 days (range=40-73 days). The prescription dose to the planning target volume (PTV) was delivered in 25 to 30 (median 28) daily fractions. The EBRT median dose to the pelvis and gross tumor volume were 50.4 Gy (range=45-56.25) and 61.6 Gy (range=45-70.4), respectively. The 1-year, 2-year, 3-year, and 5-year overall survival rates were 92.44%, 80.81%, 78.84%, and 76.45% respectively. The actuarial 1-year, 2-year, 3-year, and 5-year disease-free survival rates were 89.5%, 83.6%, 81%, and 78.2% respectively.

conclusionThis study analyzed acute and chronic toxicity, survival, and local control in cervical cancer patients treated with IMRT followed by CT-planned high dose rate-brachytherapy. Patients demonstrated satisfactory outcomes and incidence of acute and late toxicities.

Indexed as

brachytherapyCervixHDR-BTLACCradiotherapy

Identifiers

PMID36875316
PMCPMC9949546
OpenAlexW4323295260

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.